secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001140361-25-019620
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia
--------------------------------------------------------------------------------

- Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).
- Met all key secondary endpoints; majority of participants achieved normal TG <150 mg/dL.
- Favorable safety profile; most common AE was mild injection site reactions.
- Study enrolled 1,478 participants with moderate HTG on standard-of-care lipid-lowering therapy.
- Pivotal Phase 3 CORE and CORE2 data in sHTG expected Q3 2025; potential sNDA filing by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/0001140361-25-019620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/ef20049265_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-019620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer